Fracture risk prediction with FRAX in Slovak postmenopausal women

被引:2
作者
Nemethova, Eva [1 ]
Killinger, Zdenko
Payer, Juraj
机构
[1] Comenius Univ, Fac Med, Dept Internal Med 5, Bratislava 82606, Slovakia
来源
CENTRAL EUROPEAN JOURNAL OF MEDICINE | 2013年 / 8卷 / 05期
关键词
Osteoporosis; Fracture risk; FRAX; Treatment thresholds; OSTEOPOROSIS; DIAGNOSIS; UK; GUIDELINES; MANAGEMENT; TOOL;
D O I
10.2478/s11536-013-0205-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current Slovak treatment thresholds in osteoporosis are based on bone mineral density (BMD) or a previous fracture. Some patients at high risk for fractures may not be identified. FRAX (Fracture Risk Assessment Tool) is based on patient risk profile assessment and calculates 10-year fracture risks. Using FRAX, treatment initiation could be more patient-specific. To evaluate the risk profile with FRAX in slovak postmenopausal women, to identify those at high risk of fracture according to NOF (National Osteporosis Foundation) intervention thresholds based on FRAX and to compare this approach to current treatment thresholds. We measured BMD at lumbar spine, femoral neck, total hip and calculated 10-year absolute fracture risks with the slovak version of FRAX in 365 patients. Average risk of major osteoporotic fracture was 10,39% and hip fracture 3,00%. 109 patients were eligible for treatment according to actual treatment criteria (88 based on BMD and 21 with previous fracture). In addition, 57 high risk osteopenic patients were identified by NOF thresholds using FRAX, who should be also considered for treatment. Using FRAX and NOF thresholds it's possible to identify high risk patients who don't fulfill current treatment criteria but may profit from treatment.
引用
收藏
页码:571 / 576
页数:6
相关论文
共 32 条
[1]  
[Anonymous], 2010, CLIN GUID PREV TREAT
[2]  
[Anonymous], 2012, ROR SJUKD 2012 OST A
[3]   What was your fracture risk evaluated by FRAXA® the day before your osteoporotic fracture? [J].
Aubry-Rozier, Berengere ;
Stoll, Delphine ;
Krieg, Marc-Antoine ;
Lamy, Olivier ;
Hans, Didier .
CLINICAL RHEUMATOLOGY, 2013, 32 (02) :219-223
[4]   Disparate Outcomes from Applying UK and US Osteoporosis Treatment Guidelines [J].
Bolland, Mark J. ;
Grey, Andrew .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (04) :1856-1860
[5]   Osteoporosis diagnosis and therapy according to the 2010 guidelines [J].
Braun, J. ;
Pfeilschifter, J. .
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2010, 69 (04) :327-338
[6]   Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria [J].
Bruyere, O. ;
Fossi, M. ;
Zegels, B. ;
Leonori, L. ;
Hiligsmann, M. ;
Neuprez, A. ;
Reginster, J. -Y. .
RHEUMATOLOGY INTERNATIONAL, 2013, 33 (04) :973-978
[7]   Fracture Risk Assessment: State of the Art, Methodologically Unsound, or Poorly Reported? [J].
Collins, Gary S. ;
Michaelsson, Karl .
CURRENT OSTEOPOROSIS REPORTS, 2012, 10 (03) :199-207
[8]   Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK [J].
Compston, J. ;
Cooper, A. ;
Cooper, C. ;
Francis, R. ;
Kanis, J. A. ;
Marsh, D. ;
McCloskey, E. V. ;
Reid, D. M. ;
Selby, P. ;
Wilkins, M. .
MATURITAS, 2009, 62 (02) :105-108
[9]   Impact of UK National Guidelines based on FRAX®- comparison with current clinical practice [J].
Crabtree, N. J. ;
Bebbington, N. A. ;
Chapman, D. M. ;
Wahid, Y. S. ;
Ayuk, J. ;
Boivin, C. M. ;
Cooper, M. S. ;
Gittoes, N. J. L. .
CLINICAL ENDOCRINOLOGY, 2010, 73 (04) :452-456
[10]   Clinical Risk Factors for Osteoporosis in Ireland and the UK: A Comparison of FRAX and QFractureScores [J].
Cummins, N. M. ;
Poku, E. K. ;
Towler, M. R. ;
O'Driscoll, O. M. ;
Ralston, S. H. .
CALCIFIED TISSUE INTERNATIONAL, 2011, 89 (02) :172-177